Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Joplin (Liverpool (Merseyside), United Kingdom), D. Mclenaghan (Liverpool (Merseyside), United Kingdom), L. Jones (Liverpool (Merseyside), United Kingdom), R. Robinson (Liverpool (Merseyside), United Kingdom), K. Hunter (Liverpool (Merseyside), United Kingdom), C. Lowe (Liverpool (Merseyside), United Kingdom), V. Flynn (Liverpool (Merseyside), United Kingdom), L. Root (Liverpool (Merseyside), United Kingdom), H. Burhan (Liverpool (Merseyside), United Kingdom). The real world effectiveness and effect on adherence with inhaled asthma therapy of 1 year of Severe Asthma Monoclonal Antibody Treatment. 2267

Member's Comments

No comment yet.

Related content which might interest you: Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment? Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Treatment of asthma above and beyond anti IgE: an update for the clinician The use of biologicals in asthma treatment Source: International Congress 2018 – Difficult paediatric lung disease Year: 2018 Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Effect of 1 year treatment with inhaled corticosteroids with electronically assessed adherence on height growth in children with asthma Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015 Characteristics of asthma patients responding to anti-IgE therapy Source: Annual Congress 2013 –Diagnosis and management of respiratory diseases Year: 2013 Clinical effectiveness of anti-IgE therapy in allergic severe asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016 Total and free IgE in evolution of severe asthma after omalizumab treatment Source: International Congress 2016 – Asthma management Year: 2016 Adherence with inhaled corticosteroids in asthma: Does pregnancy lead to improved adherence? Source: International Congress 2014 – Asthma: still a heterogeneous condition! Year: 2014 Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 BTS Difficult Asthma Registry: Effect of omalizumab dosing table expansion on size of population of severe persistent allergic asthma patients potentially eligible for omalizumab therapy Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012 Experience with omalizumab in patients with moderate and severe asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Excess inhaled corticosteroid adherence may be a marker of uncontrolled asthma Source: Annual Congress 2013 –Quality of diagnosis and assessment in primary care Year: 2013 Pattern of asthma control and inhaled corticosteroid (ICS) use in an Australian asthma population Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 Adherence to the treatment of patients with bronchial asthma Source: International Congress 2015 – Is asthma always an easy disease to diagnose and manage? Year: 2015 Clinical features of asthma complicated with eosinophilic otitis media and the effect of treatment with the anti-IgE monoclonal antibody omalizumub Source: International Congress 2015 – Co-existing diseases and asthma Year: 2015 Efficacy and safety of indacaterol acetate on ICS background therapy in asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 The ’real-life’ long-term efficacy of omalizumab in severe persistent IgE-mediated allergic asthma in Malta Source: International Congress 2016 – Asthma management Year: 2016 Comparative effectiveness of paediatric asthma step-up options: Increasing ICS dose vs adding separate LABA Source: International Congress 2014 – Paediatric asthma: what is new for the clinician? Year: 2014